CCL22 Antibody, HRP conjugated

說(shuō)明書

中文名稱：

CCL22兔多克隆抗體, HRP偶聯(lián)
貨號(hào)：

CSB-PA05895B0Rb
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CCL22 Polyclonal antibody
Uniprot No.：

O00626
基因名：

CCL22
別名：

A 152E5.1 antibody; ABCD 1 antibody; ABCD1 antibody; C C motif chemokine 22 antibody; CC chemokine STCP 1 antibody; CC chemokine STCP-1 antibody; ccl 22 antibody; Ccl22 antibody; CCL22_HUMAN antibody; Chemokine (C C motif) ligand 22 antibody; DC/B CK antibody; DCBCK antibody; Macrophage-derived chemokine antibody; MDC antibody; MDC(1-69) antibody; MDC(7-69) antibody; MGC34554 antibody; SCYA22 antibody; Small inducible cytokine subfamily A (Cys Cys) member 22 antibody; Small inducible cytokine subfamily A; member 22 antibody; Small-inducible cytokine A22 antibody; STCP 1 antibody; STCP1 antibody; Stimulated T cell chemotactic protein 1 antibody; Stimulated T-cell chemotactic protein 1 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human C-C motif chemokine 22 protein (25-82AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active.
基因功能參考文獻(xiàn)：
1. MDC might serve as a marker of pharmacological therapy response in major depressive disorder PMID: 28898872
2. blood CCL22 levels were positively associated with IgE sensitization at age 2. A high cord blood CCL22/CXCL10 chemokine ratio was significantly associated with a higher risk of allergic sensitization at age 3. PMID: 27863395
3. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 signaling axis. PMID: 28039457
4. Elevations in serum MDC and BLC were independently associated with the significant risk of early stage lung adenocarcinoma, even in non-smokers and in stage IA patients. PMID: 27811371
5. CCL22 plays an important role in supporting gastric cancer development presumably by increasing the percentage of regulatory T cells in the tumor microenvironments. CCL22 levels in sera have a predictive value for gastric cancer peritoneal metastasis and the early recurrence. PMID: 28501127
6. The CCL22-mediated enhancement of antitumor responses is however not due to conversion, but rather to redirection of existing regulatory T cells to the site of cutaneous overexpression. PMID: 27634754
7. CCL22 and IL-37 with a co-localization in non-small cell lung cancer A549 cells inhibited the proliferation and epithelial-mesenchymal transition process PMID: 27499437
8. Our results demonstrate that CCL22 is expressed in human placenta. Decidual expression was only observed in miscarriage conditions and correlates with Treg infiltration. PMID: 25922986
9. Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. PMID: 26093920
10. type I IFN blocks the regulatory T cell-attracting chemokine CCL22 and thus helps limit the recruitment of regulatory T cells to tumors PMID: 26432403
11. First-episode psychosis patients had higher serum CCL22, which decreased substantially following antipsychotic treatment. PMID: 25970596
12. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression. PMID: 25647263
13. Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH mutation status. CCL22 should be considered a marker of immune status with potential prognostic value PMID: 25604093
14. CCL22 is a novel mediator of lung inflammation following hemorrhage and resuscitation PMID: 25136780
15. CCR4 C1014T and CCL22 C16A genetic variations were neither associated with the risk, nor with the progression of colorectal cancer in Iranian population PMID: 25148803
16. The serum CCL22 levels were affected by genetic variations at SNP rs223818. Accordingly, SNP rs223818 may play a role in the susceptibility to breast cancer. PMID: 25722218
17. Sesamin suppressed lipopolysaccharide induced CCL22 expression in monocytes through the ER/PPAR-a, the MAPK-p38 pathway, the NFkB-p65 pathway and the epigenetic regulation by suppressing histone H3/H4 acetylation in the CCL22 promoter region. PMID: 25117529
18. CCL22 could be an immune marker in ANCA-associated vasculitis. PMID: 25352172
19. Suggest that lower CCL22 levels may play an important role in the pathogenesis of multiple sclerosis in women. PMID: 24254331
20. CCL22 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
21. genetic polymorphism is not associated with breast carcinoma in Southern Iranian population PMID: 23268288
22. both CCL22 and TGF-beta1 are candidate chemoattractants for intratumoral Foxp3 (+)Tregs infiltration; however, unlike the later, CCL22 is an independent prognostic predictor of BC patients. PMID: 24124553
23. Autistic children had significantly higher serum levels of MDC than healthy controls PMID: 23782855
24. Data suggest that decreased levels of plasmatic CCL22 may contribute to CD4(+) lymphopaenia. PMID: 23265706
25. lymph node metastasis of CCR4(+) HNSCC is promoted by CCL22 in an autocrine or M2-like macrophage-dependent paracrine manner. PMID: 23180648
26. High cord blood levels of the Th2 related chemokine CCL22 were significantly associated with high total- IgE levels during the first 6 years of life, but not with specific sensitization, asthma, eczema or allergic rhinitis. PMID: 23106659
27. findings suggest that HBV infection and activity of the TGF-beta-miR-34a-CCL22 axis serve as potent etiological factors to predispose hepatocellular carcinoma patients for the development of portal vein tumor thrombus PMID: 22975373
28. results suggested that suppression of the CCL22 gene using Salmonella induced anti-inflammatory effects PMID: 21823987
29. Data suggest that variants of C-C motif chemokine 22 (CCL22) play a role in susceptibility to atopic dermatitis (AD) in a gain-of-function manner. PMID: 22125604
30. chemokine CCL22 may have a role in abdominal aortic aneurysm PMID: 20348247
31. CCL22 may be responsible for the infiltration of CD4(+)CD25(high) T cells into the pleural space of patients with tuberculous pleurisy. PMID: 20337996
32. Plasma concentration of CCL22 correlates with the frequency of circulating CD4-positive FoxP3-positive (CD4+FoxP3+) regulatory T cells (Tregs) in human T-lymphotropic virus (HTLV) type 1-infected subjects. PMID: 20525891
33. Endocrine disrupting chemicals suppressed CCL22 and IP-10 levels in cultured monocytes via, at least in part, the MKK1/2-ERK MAPK pathway and histone H4 acetylation. PMID: 19756997
34. Data show that MDC/CCL22 is present in the synovial membrane of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients and in synovial fluid of patients with RA and PsA, which would enable migration of CCR4 expressing memory cells. PMID: 19942450
35. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22, suggesting a vicious circle, leading to the progressive accumulation of the neoplastic cells. PMID: 11981828
36. Neither MDC release nor MDC mRNA was detected in any of the 3 types of fibroblasts stimulated with any of the cytokines examined. PMID: 12642832
37. Serum levels of TARC and MDC in atopic dermatitis patients were significantly higher than those found in normal controls. PMID: 15113590
38. CCL22 induced accumulation of phosphatidylinositol-(3,4,5)-trisphosphate in the leukemic T cell line CEM. CCL22 also had the ability to chemoattract human Th2 cells and CEM cells in a pertussis toxin-sensitive manner. PMID: 15187160
39. CCL17 and CCL22, which are constitutively produced by immature DCs, mediate both T cell polarization and attraction. PMID: 15210758
40. Elevated bronchial mucosal expression of MDC/CCL22 is implicated in asthma pathogenesis; its action is partly through selective development and retention, or recruitment of T helper type 2, not Th1, receptor-bearing cells. PMID: 15944327
41. MDC/CCL22 has a role in inhibiting progression of lung cancer PMID: 16453150
42. These data suggest that the CCL22 level produced by monocyte derived dendritic cells thus reflects the disease activity of Atopic dermatitis (AD) and it may also play an important role regarding the production of CCL22 in the pathogenesis of AD. PMID: 17008059
43. A trend towards a decreased allelic frequency of the A allele of the CCL22 C/A SNP as well as of the T allele of the CCL17 C/T SNP was found in MS patients compared with controls. PMID: 17967467
44. HTLV-1-infected T cells produce CCL22 through Tax and selectively interact with CCR4+CD4+ T cells, resulting in preferential transmission of HTLV-1 to CCR4+CD4+ T cells. PMID: 18178833
45. MDC/CCL22 is likely to play a role in the development of multiple sclerosis in females only, possibly influencing the intracerebral recruitment of Th2 cells, which produce anti-inflammatory cytokines PMID: 18208895
46. Significantly higher CCL22 expression is associated with gastric cancer PMID: 18224687
47. although IE86 does repress the UL144-mediated activation of a synthetic NFkB promoter, it is unable to block UL144-mediated activation of the CCL22 promoter, and this lack of responsiveness to IE86 appears to be regulated by binding of CREB. PMID: 18287226
48. serum CCR4 ligands (CCL17 and CCL22)may be useful inflammatory markers for assessing atopic dermatitis severity in children PMID: 18435706
49. Development of allergic disease is associated with a more marked Th2-like deviation already at birth, shown as increased levels of cord blood IgE and MDC (CCL22) and higher ratios of MDC (CCL22) to IP-10 (CXCL10) and I-TAC (CXCL11). PMID: 19175890
50. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. PMID: 19244125
顯示更多

收起更多
亞細(xì)胞定位：

Secreted.
蛋白家族：

Intercrine beta (chemokine CC) family
組織特異性：

Highly expressed in macrophage and in monocyte-derived dendritic cells, and thymus. Also found in lymph node, appendix, activated monocytes, resting and activated macrophages. Lower expression in lung and spleen. Very weak expression in small intestine. I
數(shù)據(jù)庫(kù)鏈接：

HGNC: 10621

OMIM: 602957

KEGG: hsa:6367

STRING: 9606.ENSP00000219235

UniGene: Hs.534347

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human